Bcr-Abl is found in more than 95% of cases with CML. The mechanism of Bcr-Abl-induced transformation is not fully understood. Bcr-Abl is a constitutively active tyrosine kinase with transforming ...

Chronic myeloid leukemia (CML) is a myeloproliferative disorder characterized by the t(9;22) translocation coding for the chimeric protein p210 BCR-ABL. The tumor suppressor phosphatase and tensin ...

Expression of CD74 by AML blasts and cell lines, and enhanced in vitro cytotoxicity of anti-CD74 antibody after interferon-gamma (IFN-γ) treatment. Background: Current NCCN guidelines recommend ...

Tuberculosis infection in chronic myeloid leukemia (CML) patients treated with imatinib. Background: The BCR-ABL fusion gene results from the translocation t(9;22). It is the hallmark of chronic ...

To support the validation and verification of new assays and to challenge the existing assays in oncology testing, Thermo Fisher Scientific launches Thermo Scientific Acrometrix BCR-ABL Panel. The ...

More than 95% of chronic myeloid leukemia (CML) and 20%-30% of acute lymphoblastic leukemia (ALL) patients express the fusion protein BCR-ABL1. The first-generation ABL tyrosine kinase inhibitor (TKI) ...

CML is a malignant clonal disorder of hematopoietic stem cells that increases not only myeloid, but also erythroid cells and platelets in the peripheral blood and induces marked myeloid hyperplasia in ...

Asuragen, Inc. has announced that it received premarket clearance from the U.S. Food and Drug Administration (FDA) for the QuantideX® qPCR BCR-ABL IS Kit for the monitoring of molecular response in ...

When you receive a diagnosis of CML, your doctor will monitor abnormal cells in your blood and bone marrow to see how well you’re responding to treatment. Treatment milestones are achieved by reducing ...

Atypical chronic myeloid leukemia (aCML) is a rare, aggressive subtype of CML. Stem cell transplants are a potentially curative treatment, but people ineligible for a transplant may still benefit from ...